VEGFA and hepatocellular carcinoma: Furthermore, combinatorial strategies are underway to determine whether the addition of tyrosine kinase inhibitors, thermal ablation, anti-VEGF antibody bevacizumab, or additional immune CPIs could augment the proportion of HCC patients responding.